Vasyutina, E., Boucas, J. M., Bloehdorn, J., Aszyk, C., Crispatzu, G., Stiefelhagen, M., Breuer, A., Mayer, P., Lengerke, C., Doehner, H., Beutner, D., Rosenwald, A., Stilgenbauer, S., Hallek, M., Benner, A. and Herling, M. (2015). The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia, 29 (10). S. 2003 - 2015. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

Full text not available from this repository.

Abstract

Dysregulated T-cell leukemia/lymphoma-1A (TCL1A), a modulator in B-cell receptor (BCR) signaling, is causally implicated in chronic lymphocytic leukemia (CLL). However, the mechanisms of the perturbed TCL1A regulation are largely unknown. To characterize TCL1A-upstream networks, we functionally screened for TCL1A-repressive micro-RNAs (miRs) and their transcriptional regulators. We identified the novel miR-484 to target TCL1A's 3'-UTR and to be downregulated in CLL. In chromatin immunoprecipitations and reporter assays, the oncogenic transcription factor of myeloid cells, EVI1, bound and activated the miR-484 promoter. Most common in CLL was a pan-EVI1 transcript variant. EVI1 protein expression revealed distinct normal-tissue and leukemia-associated patterns of EVI1/TCL1A co-regulation. EVI1 levels were particularly low in TCL1A-high CLL or such cellular subsets. Global gene expression profiles from a 337-patient set linked EVI1 networks to BCR signaling and cell survival via TCL1A, BTK and other molecules of relevance in CLL. Enforced EVI1, as did miR-484, repressed TCL1A. Furthermore, it reduced phospho-kinase levels, impaired cell survival, mitigated BCR-induced Ca-flux and diminished the in vitro ibrutinib response. Moreover, TCL1A and EVI1 showed a strongly interactive hazard prediction in prospectively treated patients. Overall, we present regressive EVI1 as a novel regulatory signature in CLL. Through enhanced TCL1A and other EVI1-targeted hallmarks of CLL, this contributes to an aggressive cellular and clinical phenotype.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Vasyutina, E.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Boucas, J. M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Bloehdorn, J.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aszyk, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Crispatzu, G.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stiefelhagen, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Breuer, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mayer, P.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Lengerke, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Doehner, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Beutner, D.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Rosenwald, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stilgenbauer, S.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hallek, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Benner, A.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Herling, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-391370
DOI: 10.1038/leu.2015.114
Journal or Publication Title: Leukemia
Volume: 29
Number: 10
Page Range: S. 2003 - 2015
Date: 2015
Publisher: NATURE PUBLISHING GROUP
Place of Publication: LONDON
ISSN: 1476-5551
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
CHRONIC LYMPHOCYTIC-LEUKEMIA; EXPRESSION; MICRORNA; PATHOGENESIS; MOUSE; 13Q14; MALIGNANCIES; APOPTOSIS; PATTERN; MIR-29Multiple languages
Oncology; HematologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/39137

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item